Implementation of trastuzumab in adjuvant treatment of breast cancer and guideline adherence in the Netherlands &
Spatial variation in stage distribution in colorectal cancer in the Netherlands

Sabine Siesling, PhD
Head of dept. Research
Comprehensive Cancer Centre North East

KNO
Integraal kankercentrum Noord Oost
Trastuzumab / Herceptin

Immunotherapy

Targets on HER2 receptor

Timeline introduction adjuvant trastuzumab

16 May 2005: presentation 2 USA studies + HERA study at ASCO
15 Sept 2005: publication new guideline
12 June 2005: NVMO advice is published
Guideline

Adjuvant trastuzumab should be used in:

- Stage I-III
- HER2 + (FISH/IHC test) women
- In combination with adjuvant chemotherapy
Aim of this study

• To identify the percentage of women with HER2-positive breast cancer

• To evaluate the implementation of trastuzumab in clinical practice

• To evaluate differences between regions in the Netherlands

Patients and methods

• Selection from the Netherlands Cancer Registry

• Inclusion:
  – women
  – invasive breast cancer (stage I-III)

• Exclusion:
  – Distant metastases
  – Neo-adjuvant chemotherapy

• Period: 1 Sept 05 – 1 Jan 07 (16 months)

• Number of patients: 14,934

• Her2 status and treatment was regularly registered
Aim of this study

• To identify the percentage of women with HER2-positive breast cancer

• To evaluate the implementation of trastuzumab in clinical practice

• To evaluate differences between regions in the Netherlands
### HER2-positivity and age

<table>
<thead>
<tr>
<th>Age</th>
<th>Patients N</th>
<th>Her2-positive %</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;40</td>
<td>785</td>
<td>22.3</td>
</tr>
<tr>
<td>40-49</td>
<td>2,802</td>
<td>15.5</td>
</tr>
<tr>
<td>50-59</td>
<td>4,006</td>
<td>14.4</td>
</tr>
<tr>
<td>60-69</td>
<td>3,599</td>
<td>11.1</td>
</tr>
<tr>
<td>70+</td>
<td>3,738</td>
<td>9.2</td>
</tr>
<tr>
<td>Total</td>
<td>14,937</td>
<td>12.6</td>
</tr>
</tbody>
</table>

% of patients with a HER2-positive tumour, by age

Vertical lines: range between different CCC regions
% of patients with HER2 status unknown / not tested, by age

Vertical lines: range between different CCC regions

Aim of this study

• To identify the percentage of women with HER2-positive breast cancer

• To evaluate the implementation of trastuzumab in clinical practice

• To evaluate differences between regions in the Netherlands
% of HER2+ patients receiving trastuzumab, by age

Vertical lines: range between different CCC regions

% of HER2+ patients receiving trastuzumab, over time

Vertical lines: range between different CCC regions
Aim of this study

- To identify the percentage of women with HER2-positive breast cancer
- To evaluate the implementation of trastuzumab in clinical practice
- To evaluate differences between regions in the Netherlands
% of HER2+ patients receiving trastuzumab, by region

![Graph showing percentage of HER2+ patients receiving trastuzumab by region.]

Conclusion (1)

- NCR: great value to evaluate the implementation of adjuvant trastuzumab since introduction
- 13% of patients has HER2-positive tumour
- % HER2-positive tumours is markedly related to age
Conclusion (2)

16 May 2005: presentation 2 USA studies + HERA study at ASCO

15 Sept 2005: publication new guideline

12 June 2005: NVMO advice is published

Sept - Dec 2005: >90% of patients received trastuzumab

Conclusion (3)

• Implementation trastuzumab fast, but with some regional variation

• Legitimate reasons to withhold trastuzumab were found for most patients (64%)
Niet altijd beste medicijn voor kankerpatiënt

UTRECHT - Kankerpatiënten krijgen in Nederland niet altijd de medicijnen waar ze het beste mee geholpen zijn. Door krappe in hun budgetten kiezen ziekenhuizen voor goedkope medicijnen die minder effectief zijn.

Patiënt krijgt duur medicijn niet meer

14 november 2007

Yes, we did